PRODUCT INFORMATION



DcR2 Polyclonal Antibody

Item No. 160755

Overview and Properties

This vial contains 200 µl of peptide affinity purified polyclonal antibody Contents:

Synonyms: TRAIL-R4; TRUNDD

Immunogen: Synthetic peptide from an internal region of human DcR2

Species Reactivity: (+) Human, other species not tested

Q9UBN6 **Uniprot No.:** Form: Liquid

-20°C (as supplied) Storage:

Stability: ≥1 year

Storage Buffer: PBS, pH 7.2 with 0.02% sodium azide


Host:

Western Blot (WB); the recommended starting dilution is 1:1,000. Other applications Applications:

were not tested, therefore optimal working concentration/dilution should be

determined empirically.

Image



Lane 1: HeLa Cell Lysate (25 ug) Lane 2: HeLa Cell Lysate (50 µg)

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/24/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Description

Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors. TRAIL/Apo2L is a new member of the TNF family and induces apoptosis of a variety of tumor cell lines. DR4 and DR5 are the recently identified functional receptors for TRAIL, and DcR1/TRID is a decoy receptor.¹⁻³ Another member of the TRAIL receptor family was more recently identified and designated DcR2, TRAIL-R4, or TRUNDD.⁴⁻⁶ DcR2 has an extracellular TRAIL-binding domain but lacks an intracellular death domain and does not induce apoptosis. Like DR4 and DR5, DcR2 transcript is widely expressed in normal human tissues. Overexpression of DcR2 attenuates TRAIL-induced apoptosis.

References

- 1. Pan, G., O'Rourke, K., Chinnaiyan, A.M., et al. The receptor for the cytotoxic ligand TRAIL. Science 276(5309), 111-113 (1997).
- 2. Pan, G., Ni, J., Wei, Y.-F., et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. *Science* **277**(5327), 815-817 (1997).
- 3. Sheridan, J.P., Marsters, S.A., Pitti, R.M., et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. *Science* **277(5327)**, 818-821 (1997).
- 4. Marsters, S.A., Sheridan, J.P., Pitti, R.M., et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. *Curr. Biol.* **7(12)**, 1003-1006 (1997).
- 5. Degli-Esposti, M.A., Dougall, W.C., Smolak, P.J., et al. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. *Immunity* **7(6)**, 813-820 (1997).
- 6. Pan, G., Ni, J., Yu, G.-L., *et al.* TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. *FEBS Lett.* **424(1-2)**, 41-45 (1998).

ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897